Presented at #ERA26:
In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: https://t.co/T3Z8pTEARK
@ERAkidney
😊👏👏 Prof. Fernando Fervenza presenting the Phase III MAJESTY Trial at the Late Breaking Clinical Trials #ERA2026. Trial compared obinutuzumab vs tacrolimus in primary membranous Nephropathy & highlighted advances in glomerular disease care @ERAkidney@fervenzaf#ERA26
Wonderful presentation by Dr. Sandra Herrmann at #ERA2026 on “Biomarker-Driven Immunotherapy for Checkpoint Inhibitor–Induced Interstitial Nephritis.”
@HerrmannMd
ERA Glasgow 2026 is happening June 3-6! Join @HerrmannMd on June 4 as she presents on Biomarker-driven Immunotherapy for checkpoint inhibitor-induced interstitial nephritis! #MayoClinicKidney
Dr. Fernando Fervenza will be presenting Efficacy and Safety of Obinutuzumab Compared with Tacrolimus in Primary Membranous Nephropathy: Topline Results of the Phase III MAJESTY Trial on June 5th at ERA Congress! #MayoClinicKidney
Most kidney trials whisper.
This one doesn’t.
@NEJM Phase 3 interim analysis in NEJM:
telitacicept cut proteinuria by 58.9% vs 8.8% placebo in high-risk IgA nephropathy.
eGFR at 39 weeks: -1.0% vs -7.7%.
Dual BAFF/APRIL blockade may be hitting disease upstream.
#IgAN #Nephrology #KidneyDisease #Glomerulonephritis
1/3
The diagnosis of TMA is challenging. It is really a pattern of injury. What is the etiopathogenesis? How do we treat?
Machine Learning can help.
So thrilled to share this paper, led by
@LadanZand@MayoClinicNeph@MayoClinicPath https://t.co/EGF1Gti48D
Difficult but good recent teaching case.
LM- normal appearing glomeruli but proximal tubules filled with eosinophilic granules.
IF- negative.
EM- large number of lysosomes, with degenerative changes.
Lysozyme stain 3+ positive in proximal tubules.
Dx: Lysozyme associated-tubulopathy (myelofibrosis/clinical).
Usually see this in patients with CML.
D/D: light chain proximal tubulopathy, but IF & pronase IF are negative.
60-yr old with chronic kidney disease, pulmonary nodules, and JAK2+ myelofibrosis.
Evaluation showed high levels of serum lysozyme, and lysozymuria.